Shares of companies that benefited from the pandemic have been crushed in the past few months. That's something shareholders of Fulgent Genetics (NASDAQ: FLGT) have gotten used to. The stock peaked ...
For Fulgent, revenue is driven primarily by COVID-testing volume. That number correlates well with the number of U.S. daily tests. Based on what's already known, Wall Street may be underestimating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results